ArticleAJOG global reports2026
Topical resiniferatoxin for the treatment of vestibulodynia: a prospective observational trial.
Article in AJOG global reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Vestibulodynia is the most common subtype of vulvodynia and is characterized by persitent, contact-evoked pain localized to the vulvar vestibule. Increasing evidence supports a neuropathic pain mechanism in vestibulodynia, including vestibular hyperinnervation, neuroinflammation, and overexpression of the transient receptor potential vanilloid 1 receptor. Despite this, there are no standardized treatment protocols, and available therapies often provide incomplete relief or are limited by systemic side effects. Targeted topical therapies may offer advantages by acting directly on peripheral pain generators. Resiniferatoxin, a highly potent transient receptor potential vanilloid 1 receptor agonist, induces long-lasting desensitization of nociceptive fibers and may represent a novel therapeutic option for vestibulodynia. Objective: To evaluate the clinical efficacy, tolerability, and neurophysiological effects of topical resiniferatoxin cream applied to the vulvar vestibule in women with vestibulodynia. Study Design: This was a prospective, observational pilot study. Premenopausal women aged ≥18 years with a diagnosis of vestibulodynia lasting at least 3 months were enrolled. Participants applied topical resiniferatoxin 10 mcg/mL cream to the vulvar vestibule once daily for 4 weeks using a standardized dosing dispenser. Outcomes included patient-reported pain intensity (visual analog scale for pain and dyspareunia), vestibular cotton swab test scores, levator ani muscle tone, and vestibular current perception thresholds at 2000, 250, and 5 Hz. Baseline and 1-month follow-up values were compared using the Wilcoxon signed-rank test and McNemar test, as appropriate. Results: Twenty-four women were enrolled (median age 31 years; median vestibulodynia duration 66 months). Most participants reported a transient, tolerable burning sensation after resiniferatoxin application; 5 women (20.8%) discontinued treatment due to local discomfort. Among participants with complete follow-up, significant improvements were observed at 1 month in provoked vulvar pain and dyspareunia, with median Visual Analog Scale reductions of 2.0 ( Conclusion: Topical resiniferatoxin was associated with meaningful reductions in vulvar pain and dyspareunia and with objective improvements in vestibular nerve fiber sensitivity in women with vestibulodynia. These findings support the role of transient receptor potential vanilloid 1 receptor-mediated peripheral mechanisms in vestibulodynia and suggest that resiniferatoxin may be a promising targeted therapy. Larger, placebo-controlled trials with longer follow-up are warranted to confirm these preliminary results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.